Coordinated Co-amplification of 8p11 and 11q13 Genomic Loci Establishes a Closed Autocrine Oncogenic Circuit in Luminal Breast Cancer with Neuroendocrine Differentiation: A Hypothesis Report with Liquid Biopsy Corroboration

The simultaneous high-level amplification of two distinct genomic loci — 8p11 (FGFR1) and 11q13 (CCND1, FGF3, FGF4, FGF19) — in a case of stage IV hormone receptor-positive (HR+), HER2-negative breast cancer with extensive neuroendocrine differentiation (BC-NED) prompted the hypothesis that these co-amplified elements form a closed autocrine oncogenic circuit: FGF ligands (FGF3/4/19) co-amplified with their cognate receptor (FGFR1/FGFR4) and a key downstream effector (CCND1/cyclin D1) create a self-sufficient mitogenic loop that operates independently of upstream hormonal input, thereby explaining observed resistance to sequential CDK4/6 inhibitor-based regimens. This report integrates: (1) published mechanistic data on FGFR1-mediated PI3K/AKT activation, FGF19–FGFR4 autocrine signaling in breast cancer, and the prognostic impact of 8p11/11q13 co-amplification; (2) population-level data from cBioPortal (17,758 breast cancer samples across 36 studies) confirming statistically significant co-occurrence of these amplifications and their association with reduced overall survival; and (3) serial liquid biopsy data (Guardant360 CDx + an independent orthogonal liquid biopsy assay, April 2026) demonstrating persistence of both amplicons in circulating tumor DNA at disease progression, co-occurring with three independent RB1 loss-of-function mutations and an emergent ESR1 D538G variant — a polyclonal resistance landscape consistent with, and extending, the proposed circuit model. To our knowledge, the conceptualization of the co-amplified FGF ligand cluster + cognate receptor + downstream effector as a structurally closed autocrine circuit has not been previously described in the BC-NED context. This framing generates specific, testable predictions and informs a rational therapeutic strategy centered on pan-FGFR1–4 inhibition.